Impact of Comorbidities in Mexican SARS-CoV-2-Positive Patients: A Retrospective Analysis in a National Cohort
Autor: | José de J Vidal-Mayo, Martin Lazcano-Hernández, Obdulia Vera-López, Ashuin Kammar-García, Patricia Aguilar-Alonso, Addí Rhode Navarro-Cruz, Juan M Vera-Zertuche, Orietta Segura-Badilla |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
Comorbidity Pulmonary Disease Chronic Obstructive 0302 clinical medicine Pregnancy Case fatality rate Retrospective analysis 030212 general & internal medicine Pregnancy Complications Infectious Aged 80 and over Smoking Clinical course General Medicine Middle Aged 030210 environmental & occupational health Mexican population Hospitalization Cardiovascular Diseases Female Coronavirus Infections Adult medicine.medical_specialty Adolescent Critical Care Coronavirus disease 2019 (COVID-19) Critical Illness Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Pneumonia Viral National cohort Betacoronavirus Immunocompromised Host Young Adult 03 medical and health sciences Diabetes Mellitus medicine Humans Obesity Renal Insufficiency Chronic Mexico Pandemics Aged Proportional Hazards Models Retrospective Studies Gynecology SARS-CoV-2 business.industry COVID-19 Respiration Artificial Asthma Critical illness business |
Zdroj: | Revista de investigaci�n Cl�nica. 72 |
ISSN: | 0034-8376 |
Popis: | espanolAntecedentes: el brote de la enfermedad por coronavirus de 2019 es un desafio importante para los sistemas de atencion medica de todo el mundo. Objetivo: El objetivo del estudio fue evaluar el impacto de las comorbilidades en la tasa de letalidad (RFC) y el desarrollo de eventos adversos en pacientes positivos para el sindrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2) en la poblacion mexicana. Materiales y metodos: Analizamos los datos de 13,842 pacientes con SARS-CoV-2 confirmados por laboratorio en Mexico entre el 1 de enero de 2020 y el 25 de abril de 2020. Investigamos el riesgo de muerte y el desarrollo de eventos adversos (hospitalizacion, neumonia, intubacion orotraqueal e ingreso a la unidad de cuidados intensivos [UCI], comparando el numero de comorbilidades de cada paciente. Resultados: La edad media de los pacientes fue de 46,6 ± 15,6 anos, el 42,3% (n = 5853) de los casos fueron mujeres, el 38,8% de los pacientes fueron hospitalizados, el 4,4% fueron intubados, el 29,6% desarrollo neumonia y el 4,4% presento enfermedad critica. El CFR fue del 9,4%. El riesgo de hospitalizacion (odds ratio [OR] = 3,1, intervalo de confianza [IC] del 95%: 2,7-3,7), neumonia (OR = 3,02, IC del 95%: 2,6-3,5), ingreso en la UCI (OR = 2, 95% IC: 1,5-2,7) y la RFC (razon de riesgo = 3,5, IC del 95%: 2,9-4,2) fue mayor en pacientes con tres o mas comorbilidades que en pacientes con 1, 2 o sin comorbilidades. Conclusiones: El numero de comorbilidades puede ser un factor determinante en la evolucion clinica y sus resultados en pacientes con SRAS-CoV-2 positivo. EnglishBackground: The coronavirus disease 2019 outbreak is a significant challenge for health-care systems around the world. Objective: The objective of the study was to assess the impact of comorbidities on the case fatality rate (CFR) and the development of adverse events in patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Mexican population. Materials and methods: We analyzed the data from 13,842 laboratory-confirmed SARS-CoV-2 patients in Mexico between January 1, 2020, and April 25, 2020. We investigated the risk of death and the development of adverse events (hospitalization, pneumonia, orotracheal intubation, and intensive care unit [ICU] admission), comparing the number of comorbidities of each patient. Results: The patient mean age was 46.6 ± 15.6 years, 42.3% (n = 5853) of the cases were women, 38.8% of patients were hospitalized, 4.4% were intubated, 29.6% developed pneumonia, and 4.4% had critical illness. The CFR was 9.4%. The risk of hospitalization (odds ratio [OR] = 3.1, 95% confidence interval [CI]: 2.7-3.7), pneumonia (OR = 3.02, 95% CI: 2.6-3.5), ICU admission (OR = 2, 95% CI: 1.5-2.7), and CFR (hazard ratio = 3.5, 95% CI: 2.9-4.2) was higher in patients with three or more comorbidities than in patients with 1, 2, or with no comorbidities. Conclusions: The number of comorbidities may be a determining factor in the clinical course and its outcomes in SARS-CoV-2-positive patients. |
Databáze: | OpenAIRE |
Externí odkaz: |